Off-site Stability Storage Facility Expands Capacity - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Off-site Stability Storage Facility Expands Capacity



Parameter Stability Storage has expanded by 30% its stability storage space for products that require International Conference on Harmonization (ICH)-specified environmental conditions.

The company’s stability storage rooms and chambers are fully validated to meet strict temperature, humidity, and uniformity controls. Chambers and rooms are monitored 24/7 and are cGMP compliant.

Parameter Stability Storage rooms and chambers have been mapped and validated for FDA-mandated long-and short-term shelf life studies under various temperature and humidity requirements.

In addition, the company offers back-up contingency storage to businesses whose own stability storage facilities prove inadequate because of space constraints, disastrous weather conditions, or electrical failures.

Source: Parameter Stability Storage

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
29%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here